Fitzgerald & Vleggaar (2011): Facial Volume Restoration of the Aging Face with Poly-L-Lactic Acid
R. Fitzgerald, D. Vleggaar · Dermatologic Therapy, 2011PMID: 21276155
Supports: Foundational review establishing PLLA as a collagen biostimulator (not a filler) that volumises tissue in a gradual, progressive, and predictable manner. Covers current injection techniques, optimal treatment areas based on evolving understanding of facial ageing, and critical technical differences between biostimulatory agents and replacement fillers.
Limitations: Narrative review, not a clinical trial. No quantitative efficacy data. Emphasises that outcomes depend on patient tissue quality and selection.
View on PubMed →Fabi et al. (2024): Effectiveness and Safety of Sculptra Poly-L-Lactic Acid Injectable Implant in the Correction of Cheek Wrinkles
S. Fabi, T. Hamilton, B. LaTowsky, R. Kazin, K. Marcus, F. Mayoral, J. Joseph, D. Hooper, S. Shridharani, J. Hicks, D. Brasater, F. Weinberg, I. Prygova · Journal of Drugs in Dermatology, 2024PMID: 38206151
Supports: Randomised controlled trial (2:1, NCT04124692) of PLLA-SCA for moderate/severe cheek wrinkles. Responder rates significantly higher vs no-treatment control at months 7 (66.2% vs 38.6%, P=0.0043), 9 (70.6% vs 31.1%, P<0.0001), and 12 (71.6% vs 26.1%, P<0.0001). Investigators reported improvements in skin radiance (>95%), tighter appearance (>88%), jawline contour (>85%). Patient satisfaction: firmness (91%+), natural-looking results (85%+), desire for repeat treatment (84%+). Durable over 12 months.
Limitations: Industry-sponsored (Galderma). Specific to newer PLLA-SCA formulation (150mg, 8mL reconstitution); results may not be directly comparable to original Sculptra. No-treatment control (not sham injection). Adverse events mostly mild with no serious events.
View on PubMed →Brown et al. (2011): Subject Global Evaluation and Subject Satisfaction Using Injectable Poly-L-Lactic Acid versus Human Collagen for Nasolabial Fold Wrinkles
S.A. Brown, R.J. Rohrich, L. Baumann, F.S. Brandt, S. Fagien, S. Glazer, J.M. Kenkel, N.J. Lowe, G.D. Monheit, R.S. Narins, M.I. Rendon, W.P. Werschler · Plastic and Reconstructive Surgery, 2011PMID: 21460676
Supports: Randomised subject-blinded multicentre RCT (PLLA N=116, collagen N=117; NCT00444210/NCT00444353). PLLA subjects reported significantly higher Subject Global Evaluation scores vs collagen from month 3-13 (P<0.001). PLLA improvement: 99% at week 3, 91% at month 13, 81% at month 25. Collagen declined from 96% at week 3 to 15% at month 13. Subject satisfaction maintained >80% for PLLA at 25 months.
Limitations: Unequal follow-up (PLLA 25 months vs collagen 13 months). Subject-blinded but not investigator-blinded. Secondary endpoint analysis from a larger efficacy study.
View on PubMed →Christen M.O. (2022): Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA)
M.O. Christen · Clinical, Cosmetic and Investigational Dermatology, 2022PMID: 35761856
Supports: Comprehensive review of PLLA as the first and most investigated collagen stimulator for off-facial body applications. Covers neck/chest, buttocks, abdomen, upper arms, thighs, knees, and hands. PLLA associated with long-lasting efficacy, high patient satisfaction, and good safety profile with mainly minor adverse events. Addresses volume loss, skin laxity, cellulite, striae distensae, and wrinkles.
Limitations: Review article; available published data on body applications still limited. Most referenced studies are small or observational. Body applications represent off-label use in many jurisdictions. State-of-the-art basis for further development needed.
View on PubMed →Nikolis A. et al. (2021): Evaluation of Cannula Safety in Injection of Poly-L-Lactic Acid
A. Nikolis, L.E. Avelar, K.M. Enright · Clinical, Cosmetic and Investigational Dermatology, 2021PMID: 34140793
Supports: Retrospective chart review (N=27 patients, 82 treatment sessions) of cannula-based PLLA (Sculptra Aesthetic) injection in face/neck. Total 7 AEs from 82 sessions (8.54%), with 6/27 patients experiencing at least one AE (22.22%). Mild bruising most common (57.14% of AEs). All AEs resolved with follow-up care. Cannula fanning technique proposed to create more uniform product placement and reduce nodule formation vs needle.
Limitations: Small single-centre retrospective study (N=27). No direct needle comparison group. One moderate AE (nodule) possibly related to concomitant treatment, not PLLA alone.
View on PubMed →Hyun M.Y. et al. (2015): Efficacy and Safety of Injection with Poly-L-Lactic Acid Compared with Hyaluronic Acid for Correction of Nasolabial Fold
M.Y. Hyun, Y. Lee, Y.A. No, K.H. Yoo, M.N. Kim, C.K. Hong, S.E. Chang, C.H. Won, B.J. Kim · Clinical and Experimental Dermatology, 2015PMID: 25319932
Supports: Multicentre randomised evaluator-blinded comparative study of PLA vs biphasic HA for moderate-to-severe nasolabial folds. At week 24, mean WSRS improvement: PLA 2.09 ± 0.68 vs HA 1.54 ± 0.65. PLA demonstrated noninferior efficacy to HA at 6 months. Both injections well tolerated; adverse reactions mild and transient.
Limitations: 24-week follow-up only; long-term comparison not assessed. Single anatomical site (nasolabial folds). Novel PLA formulation may differ from standard Sculptra.
View on PubMed →*PRP London Clinic provides these references for educational purposes. Our Clinical Board regularly reviews emerging peer-reviewed literature to ensure our protocols align with the latest advancements in regenerative medicine.